TD Cowen Upgrades Pacira Pharmaceuticals (PCRX) to Outperform, 'Anticipate Sentiment Reversal In 2H23'

TD Cowen analyst Borisk Peaker upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Market Perform to Outperform with a price target of $50.00.

The analyst comments "Pacira missed top-line revenue and margins and lowered FY23 guidance, which we believe is already captured in the valuation. Multiple initiatives/catalysts are aimed at addressing these issues. At current negative sentiment, we see very favorable risk/reward and as such we maintain our $50/share price target while upgrading our rating to Outperform."

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $36.71 yesterday.

You May Also Be Interested In

• Deutsche Bank Upgrades Target Hospitality (TH) to Buy
• Okta, Inc (OKTA) PT Raised to $170 at Cantor Fitzgerald Ahead of Q2 Results
• William Blair Upgrades Moderna (MRNA) to Outperform, 'we believe Moderna has a clear line of sight to revenue diversification from the COVID business